跳至主要内容
临床试验/NL-OMON51392
NL-OMON51392尚未招募4 期

Personalized tacrolimus treatment for pediatric kidney transplant recipients by using a dosing algorithm and a once-daily tacrolimus formulation. - TACKI (Tacrolimus dosing in children with donor kidney)

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 28 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • - Age 2-18 years old
  • - Patients to be transplanted with a kidney allograft
  • - Patients receiving a kidney from a blood group ABO-compatible donor
  • - Patients who will receive tacrolimus as part of their initial
  • immunosuppressive therapy
  • - Signed written informed consent

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • - Recipients of a non-renal organ transplant at the same occasion
  • - Recipients of a blood group ABO-incompatible kidney allograft
  • - Recipients of an HLA-incompatible kidney allograft (positive cross-match)
  • - Recipients receiving tacrolimus as immunosuppressive treatment within the
  • preceding 28 days.
  • - Recipients using medication known to have a pharmacokinetic (drug-drug)
  • interaction with tacrolimus
  • Extra exclusion criteria for participation in study part B:
  • - Children who are not able to swallow a once-daily tacrolimus capsule
  • - Children with changes in the administration of drugs interacting with
  • tacrolimus around the switch to the once-daily formulation

研究者

相似试验